DBV Technologies (DBVT) Stock Price, News & Analysis

Company Overview

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Key Stats

• Today's Range: $9.81 to $9.98
• 50-Day Range: $8.51 to $11.54
• 52-Week Range: $2.20 to $12.78
• Volume: 2,192 shs
• Average Volume: 35,499 shs
• Market Capitalization: $273.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.75
• Consensus Rating: Moderate Buy

DBV Technologies Stock Analysis - MarketRank™

DBV Technologies scored higher than 69% of companies evaluated by MarketBeat, and ranked 299th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

DBV Technologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

DBV Technologies has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for DBV Technologies are expected to grow in the coming year, from ($7.05) to ($5.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DBV Technologies is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of DBV Technologies is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

DBV Technologies has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.04% of the float of DBV Technologies has been sold short.

Short Interest Ratio / Days to Cover

DBV Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DBV Technologies has recently decreased by 17.73%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DBV Technologies does not currently pay a dividend.

Dividend Growth

DBV Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.04% of the float of DBV Technologies has been sold short.

Short Interest Ratio / Days to Cover

DBV Technologies has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DBV Technologies has recently decreased by 17.73%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 1.51

News Sentiment

DBV Technologies has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for DBV Technologies this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for DBVT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DBV Technologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,761.00 in company stock.

Percentage Held by Insiders

Only 1.44% of the stock of DBV Technologies is held by insiders.

Percentage Held by Institutions

71.74% of the stock of DBV Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DBVT Stock Analysis - Frequently Asked Questions

How have DBVT shares performed this year?

DBV Technologies' stock was trading at $3.09 at the start of the year. Since then, DBVT shares have increased by 223.3% and is now trading at $9.99.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) posted its earnings results on Tuesday, July, 29th. The company reported ($1.55) EPS for the quarter, missing the consensus estimate of ($0.21) by $1.34. The company earned $1.74 million during the quarter, compared to the consensus estimate of $0.64 million. DBV Technologies had a negative trailing twelve-month return on equity of 287.15% and a negative net margin of 3,220.49%.

When did DBV Technologies' stock split?

DBV Technologies shares reverse split on the morning of Friday, November 29th 2024.The 1-5 reverse split was announced on Monday, November 11th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Who are DBV Technologies' major shareholders?

DBV Technologies' top institutional investors include Vivo Capital LLC (3.85%), Adage Capital Partners GP L.L.C. (3.85%), MPM Bioimpact LLC (3.85%) and Nan Fung Trinity HK Ltd. (0.14%). Insiders that own company stock include Pharis Mohideen, Daniel B Soland, Timothy E Morris and Adora Ndu.
View institutional ownership trends.

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that DBV Technologies investors own include Meta Platforms (META), Pfizer (PFE), Novavax (NVAX), NVIDIA (NVDA), OPKO Health (OPK), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 8/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DBVT
• CIK: 1613780
• Web: www.dbv-technologies.com
• Phone: (315) 542-7878
• Fax: 33-1-43-26-10-83
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for DBV Technologies: $14.75
• High Price Target: $21.00
• Low Price Target: $7.25
• Potential Upside/Downside: +48.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.77)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$113.92 million
• Net Margins: -3,220.49%
• Pretax Margin: -3,217.23%
• Return on Equity: -287.15%
• Return on Assets: -138.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.45
• Quick Ratio: 2.45

Sales & Book Value

• Annual Sales: $4.15 million
• Price / Sales: 65.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.15 per share
• Price / Book: 3.15

Miscellaneous

• Outstanding Shares: 27,390,000
• Free Float: 26,996,000
• Market Cap: $271.68 million
• Optionable: Optionable
• Beta: -0.58